[1. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56(1):33-9.10.1001/archneur.56.1.33]Search in Google Scholar
[2. Fisone G, Bezard E. Molecular mechanisms of L-DOPA-induced dyskinesia. Int Rev Neurobiol 2011; 98:95-122. doi: http://dx.doi.org/10.1016/B978-0-12-381328-2.00004-310.1016/B978-0-12-381328-2.00004-3]Search in Google Scholar
[3. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Movement Dis 2010; 25(15):2649-53. doi: http://dx.doi.org/10.1002/mds.2342910.1002/mds.23429]Search in Google Scholar
[4. Luginger E, Wenning G, Bösch S, Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson’s disease. Movement Dis 2000; 15(5):873-8.10.1002/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I]Search in Google Scholar
[5. Calixto J. Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents). Brazilian J Med Biol Res 2000; 33(2):179-89.10.1590/S0100-879X2000000200004]Search in Google Scholar
[6. Rahimi-Madiseh M, Lorigoini Z, Zamani-Gharaghoshi H, Rafieian-Kopaei M. Berberis vulgaris: specifications and traditional uses. Iran J Basic Med Sci 2017; 20(5):569-87. doi: http://dx.doi.org/10.22038/IJBMS.2017.8690]Search in Google Scholar
[7. Schober A. Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP. Cell Tiss Res 2004; 318(1):215-24. doi: http://dx.doi.org/10.1007/s00441-004-0938-y10.1007/s00441-004-0938-y]Search in Google Scholar
[8. Lee CS, Cenci MA, Schulzer M, Björklund A. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson’s disease. Brain 2000; 123(7):1365-79.10.1093/brain/123.7.1365]Search in Google Scholar
[9. Paquette MA, Anderson AM, Lewis JR, Meshul CK, Johnson SW, Berger SP. MK-801 inhibits LDOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism. Neuropharmacology 2010; 58(7):1002-8. doi: http://dx.doi.org/10.1016/j.neuropharm.2010.01.00310.1016/j.neuropharm.2010.01.003]Search in Google Scholar
[10. Ardestani SB, Sahari MA, Barzegar M, Abbasi S. Some physicochemical properties of Iranian native barberry fruits (abi and poloei): Berberis integerrima and Berberis vulgaris. J Food Pharm Sci 2013;1(3). doi: http://dx.doi.org/10.15835/nbha4621111110.15835/nbha46211111]Search in Google Scholar
[11. Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery. Environ Health Persp 2001; 109(Suppl 1):69.10.1289/ehp.01109s169]Search in Google Scholar
[12. Imanshahidi M, Hosseinzadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res 2008; 22(8):999-1012. doi: http://dx.doi.org/10.1002/ptr.239910.1002/ptr.239918618524]Search in Google Scholar
[13. El-Wahab AEA, Ghareeb DA, Sarhan EE, Abu-Serie MM, El Demellawy MA. In vitro biological assessment of Berberis vulgaris and its active constituent, berberine: antioxidants, anti-acetylcholinesterase, anti-diabetic and anticancer effects. BMC Complem Alt Med 2013; 13(1):218. http://dx.doi.org/10.1186/1472-6882-13-21810.1186/1472-6882-13-218401655024007270]Search in Google Scholar
[14. Jiang W, Li S, Li X. Therapeutic potential of berberine against neurodegenerative diseases. Sci China Life Sci 2015; 58(6):564-9. http://dx.doi.org/10.1007/s11427-015-4829-010.1007/s11427-015-4829-0582353625749423]Search in Google Scholar
[15. Ahmed T, Abdollahi M, Daglia M, Nabavi SF, Nabavi SM. Berberine and neurodegeneration: A review of literature. Pharmacol Rep 2015; 67(5):970-9. doi: http://dx.doi.org/10.1016/j.pharep.2015.03.00210.1016/j.pharep.2015.03.00226398393]Search in Google Scholar
[16. Kim M, Cho K-H, Shin M-S, Lee J-M, Cho H-S, Kim C-J, et al. Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson’s disease. Intern J Mol Med 2014; 33(4):870-8. doi: http://dx.doi.org/10.3892/ijmm.2014.165610.3892/ijmm.2014.165624535622]Search in Google Scholar
[17. Salar F, Ziai S, Nasri S, Roghani M, Kamalinejad M. Neuroprotective effect of aqueous extract of Berberis vulgaris L. in a model of Parkinson’s disease in rat. J Med Plants 2010; 9(36):24-216.]Search in Google Scholar
[18. Thanvi B, Lo N, Robinson T. Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J 2007; 83(980):384-8. doi: http://dx.doi.org/10.1136/pgmj.2006.05475910.1136/pgmj.2006.054759260005217551069]Search in Google Scholar
[19. Ming M, Sinnett-Smith J, Wang J, Soares HP, Young SH, Eibl G, et al. Dose-dependent AMPK-dependent and independent mechanisms of berberine and metformin inhibition of mTORC1, ERK, DNA synthesis and proliferation in pancreatic cancer cells. PloS ONE 2014; 9(12):e114573. doi: http://dx.doi.org/10.1371/journal.pone.011457310.1371/journal.pone.0114573426241725493642]Search in Google Scholar
[20. Wang N, Feng Y, Zhu M, Tsang CM, Man K, Tong Y, et al. Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism. J Cell Biochem 2010; 111(6):1426-36. doi: http://dx.doi.org/10.1002/jcb.2286910.1002/jcb.2286920830746]Search in Google Scholar
[21. Rad SZK, Rameshrad M, Hosseinzadeh H. Toxicology effects of Berberis vulgaris (barberry) and its active constituent, berberine: a review. Iran J Basic Med Sci 2017; 20(5):516. doi: http://dx.doi.org/10.22038/ijbms.2017.8676]Search in Google Scholar
[22. Liu C-S, Zheng Y-R, Zhang Y-F, Long X-Y. Research progress on berberine with a special focus on its oral bioavailability. Fitoterapia 2016; 109:274-82. doi: http://dx.doi.org/j.fitote.2016.02.00110.1016/j.fitote.2016.02.00126851175]Search in Google Scholar
[23. Bargiotas P, Konitsiotis S. Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments. Neuropsych Dis Treat 2013; 9:1605. doi: http://dx.doi.org/10.2147/NDT.S3669310.2147/NDT.S36693380815224174877]Search in Google Scholar